Ceraxon oral solution 100mg/ml 30ml №1

Name:
Cerakson solution dpr. inside. 100mgml in a vial. 30ml №1
Description:
Transparent colorless liquid. The main active substance Citicoline Release form solution Dose 100 mg / 1 ml 30 ml Pharmacological properties Pharmacodynamics Citicoline stimulates the biosynthesis of structural phospholipids of neuronal membranes, which was confirmed in studies using magnetic resonance spectroscopy. Through this action, citicoline improves membrane functions, such as the operation of ion exchange pumps and the receptors involved in them, the modulation of which is necessary for the transmission of nerve signals. Due to its ability to stabilize membranes, citicoline promotes the reabsorption of cerebral edema. Experimental studies have shown that citicoline inhibits the activation of several phospholipases (A1, A2, C and D), reducing the formation of free radicals, preventing damage to membrane systems and maintaining antioxidant defense systems, such as glutathione. Citicoline preserves the neuronal energy reserve, inhibits apoptosis and stimulates the synthesis of acetylcholine. It has been experimentally confirmed that citicoline also has a preventive neuroprotective effect in models of focal cerebral ischemia. Clinical studies have confirmed that citicoline improves the recovery of the functions of patients after ischemic stroke, which correlates with a decrease in ischemic brain damage in neuroimaging tests. In patients with traumatic brain injury, citicoline accelerates the recovery process and reduces the duration and severity of post-traumatic syndrome. Citicoline increases the level of attention and consciousness, and also has a beneficial effect on amnesia, cognitive and neurological disorders associated with cerebral ischemia. PharmacokineticsCiticoline is well absorbed when taken orally, intramuscularly or intravenously. After the above methods of application, the levels of choline in the blood plasma increase significantly. Absorption after oral administration is almost complete, and bioavailability is approximately the same as after intravenous administration. The drug is metabolized in the intestine and in the liver with the formation of choline and cytidine. Citicoline is largely distributed in brain structures, with a rapid incorporation of the choline fraction into structural phospholipids and the cytidine fraction into cytidine nucleotides and nucleic acids. Citicoline penetrates into the brain and is actively incorporated into cellular, cytoplasmic and mitochondrial membranes, forming part of the fraction of structural phospholipids. Only a small amount of the dose of the drug is excreted in the urine and feces (less than 3%). About 12% of the dose is excreted with exhaled CO2. In the excretion of the drug in the urine, 2 phases can be distinguished: the first phase, lasting about 36 hours, during which the excretion rate decreases rapidly, and the second phase, during which the excretion rate decreases much more slowly. The same is observed in exhaled CO2 – the rate of excretion decreases rapidly after about 15 hours, and then decreases much more slowly. Indications for use Treatment of neurological and cognitive impairment associated with stroke. Treatment of neurological and cognitive disorders associated with traumatic brain injury. Route of administration and doses Adults: The recommended dose for adults is from 500 to 2000 mg per day, depending on the severity of symptoms. Elderly patients: Dose adjustment is not required in elderly patients. Children: Due to limited experience in children, the drug should be used only if the expected therapeutic benefit outweighs any possible risk. Algorithm for using the drug with a dosing syringe: 1. Place the dosing syringe with the plunger fully lowered into the vial. 2. Pulling the plunger, dial the required dose of the drug, guided by the scale of the dosing syringe. 3. Take the solution inside without dilution or pre-dilute it in half a glass of water (120 ml) at room temperature. After each use, it is recommended to rinse the dosing syringe with water. Recommendations for the use of the drug in sachets: The contents of the sachet can be drunk immediately after opening without dilution or diluted before taking in half a glass of water (120 ml) at room temperature. In case of dilution, the prepared solution is not subject to storage and is recommended for use immediately after preparation. Use during pregnancy and lactation There are insufficient data on the use of citicoline in pregnant women. Ceraxon® during pregnancy should not be prescribed unless clearly necessary. The use of the drug is permissible only in cases where the expected benefit outweighs the potential risk. When prescribing Ceraxon® during lactation, women should stop breastfeeding, since there are no data on the excretion of citicoline in human milk. Ceraxon® contains sorbitol (E420) as an excipient, therefore patients with hereditary fructose intolerance should not take this medicinal product. Ceraxon® contains parahydroxybenzoate in the form of propyl ether (E217) and methyl ester (E218), which may cause allergic reactions (possibly delayed). If during the use of the drug the symptoms persist or the condition worsens, it is necessary to stop using the drug and consult a doctor. Interaction with other drugsCiticoline enhances the effects of L-dihydroxyphenylalanine (L-DOPA). It should not be administered simultaneously with centrophenoxine and other medicinal products containing meclofenoxate. Contraindications Hypersensitivity to citicoline or any of the excipients of the drug. Increased tone of the parasympathetic nervous system. Composition solution for oral administration 100 mg / ml 1 ml of the drug contains: Active substance: sodium citicoline 104.5 mg (equivalent to 100.0 mg citicoline); Excipients: sorbitol (E420) glycerol (E422) methyl parahydroxybenzoate (E218) propyl parahydroxybenzoate (E217) sodium citrate dihydrate (E331) sodium saccharinate (E954) strawberry flavor (strawberry essence 1487-S-Lucta) potassium sorbate (E202) citric acid (E330) ) Purified water Overdose No cases of overdose have been reported. Side effects Very rare (< 1/10,000), including individual reports: Mental disorders: hallucinations. Nervous system disorders: severe headache, dizziness. Vascular disorders: arterial hypertension, arterial hypotension. Respiratory, thoracic and mediastinal disorders: shortness of breath. Gastrointestinal disorders: nausea, vomiting, sometimes diarrhea. Skin and subcutaneous tissue disorders: hyperemia, urticaria, rash, purpura. General disorders and disorders at the injection site: chills, edema. Immune system disorders: hypersensitivity reactions, anaphylactic shock. Reporting Suspected Adverse Reactions It is important to report suspected adverse reactions after drug registration. This will allow continuous monitoring of the benefit-risk ratio of the medicinal product. If an adverse reaction occurs that is indicated in this package leaflet or not mentioned in it, patients are advised to contact their doctor. Storage conditionsStore at a temperature not exceeding 25 °C. Keep out of the reach of children. Buy Ceraxon oral solution 100mg/ml 30ml №1 Price for Ceraxon oral solution 100mg/ml 30ml №1